FF
NBIX icon

FourThought Financial’s Neurocrine Biosciences NBIX Stock Holding History

FourThought Financial’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$9K Buy
87
+58
+200% +$5.88K ﹤0.01% 1063
2022
Q2 		$3K Hold
29
– – ﹤0.01% 1266
2022
Q1 		$3K Hold
29
– – ﹤0.01% 1303
2021
Q4 		$2K Sell
29
-58
-67% -$5.33K ﹤0.01% 1374
2021
Q3 		$8K Hold
87
– – ﹤0.01% 1144
2021
Q2 		$8K Hold
87
– – ﹤0.01% 1144
2021
Q1 		$8K Hold
87
– – ﹤0.01% 1104
2020
Q4 		$8K Buy
+87
New +$8.4K ﹤0.01% 1067

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

FourThought Financial's NBIX Position: Q3 2022 in Review

FourThought Financial increased its Neurocrine Biosciences (NBIX) stake by 200% in Q3 2022, buying an estimated $5.88K and bringing the position to 87 shares worth $9K. The position accounts for ﹤0.01% of the portfolio, ranked #1063.

FourThought Financial first reported a position in NBIX in Q4 2020 and has held it in 8 quarters since. 467 funds tracked by Wall St. Rank hold NBIX as of Q3 2022.

  • FourThought Financial held 87 shares of Neurocrine Biosciences worth $9K as of Q3 2022.
  • FourThought Financial bought 58 Neurocrine Biosciences shares in Q3 2022, an estimated $5.88K.
  • Neurocrine Biosciences made up ﹤0.01% of FourThought Financial's portfolio in Q3 2022, its #1063 holding.
  • FourThought Financial first reported a position in Neurocrine Biosciences in Q4 2020 and has held it in 8 quarters since.
  • 467 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2022.

Based on FourThought Financial's 13F filing for Q3 2022, filed 21 Nov 2022.